Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine.
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.
a Institut Pasteur , Invasive Bacterial Infections Unit and National Reference Centre for Meningococci , Paris , France.
Eva
E
Hong
a Institut Pasteur , Invasive Bacterial Infections Unit and National Reference Centre for Meningococci , Paris , France.
Aude
A
Terrade
a Institut Pasteur , Invasive Bacterial Infections Unit and National Reference Centre for Meningococci , Paris , France.
Muhamed-Kheir
MK
Taha
D001770:Blood Bactericidal Activity; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D007115:Immunization Schedule; D017056:Medical Laboratory Personnel; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D013997:Time Factors
C570015:4CMenB vaccine; D022401:Meningococcal Vaccines
Neisseria meningitidis; immunogenicity; laboratory workers; safety; vaccine